Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 4 1Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

Cisplatin 30Magnetic Resonance Spectroscopy 23Carboplatin 23pembrolizumab 21Paclitaxel 20Gemcitabine 19Specimen Handling 16Drug Therapy 15Dexamethasone 15Radiotherapy 14Nivolumab 14Doxorubicin 14Bevacizumab 14atezolizumab 13Oxaliplatin 13Cyclophosphamide 13Radiation 11Pemetrexed 11Cytarabine 11venetoclax 10Vincristine 10Prednisone 10Docetaxel 10Capecitabine 10Trastuzumab 9Temozolomide 8Rituximab 8Platinum 8Ipilimumab 8Fluorouracil 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Medrol Veriderm × 1 year × Clear all
NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡